Please ensure Javascript is enabled for purposes of website accessibility

How Bad News for Xeljanz Could Affect Pfizer's Fortunes

By Keith Speights and Brian Orelli, PhD - Feb 11, 2021 at 6:09AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big drugmaker hoped for better news from a safety study of its blockbuster drug.

Pfizer (PFE 0.67%) has enjoyed plenty of good news lately with its successful COVID-19 vaccine. However, the big drugmaker recently announced disappointing results from a post-marketing safety study of autoimmune disease drug Xeljanz. In this Motley Fool Live video recorded on Feb. 3, 2021, Fool.com contributors Keith Speights and Brian Orelli discuss how the bad news for Xeljanz could affect Pfizer's fortunes.

Keith Speights: Now, there was a story from last week that wasn't such good news for Pfizer. They announced results from a post-marketing safety study of their blockbuster autoimmune disease drugs, Xeljanz. What they said was that individuals receiving Xeljanz were more likely to develop the major adverse cardiovascular events like heart attack and stroke, and more likely to have cancer than those receiving drugs such as Humira and Enbrel. Brian, what do you think are the likely repercussions from Pfizer from this news?

Brian Orelli: I mean, I think it's a real blow, not only Pfizer, back to the whole -- so I think this is a JAK Inhibitor, right?

Speights: Right.

Orelli: Yeah. I think it's a big blow to the entire JAK inhibitor. Probably four or five or six companies that have JAK inhibitors and so I think this going to be a big blow, not just to Pfizer but to very company that has JAK inhibitor. It's quite possible that it's a class effect.

Speights: I'm not sure that this is necessarily going to lead to that doomsday scenario where they have to yank Xeljanz from the market. But I would not be surprised if they had to change the label and have more restrictions and it definitely could impact sales. This is a drug, a blockbuster drug, that's generated a lot of growth for Pfizer in recent years. It's certainly not good news but it's not news that they can't overcome, but certainly not something they had hoped.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.23 (0.67%) $0.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.